Is It Time for New Thinking About High-Density Lipoprotein?

Is It Time for New Thinking About High-Density Lipoprotein? Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis, Thrombosis, and Vascular Biology Wolters Kluwer Health

Is It Time for New Thinking About High-Density Lipoprotein?

Loading next page...
 
/lp/wolters_kluwer/is-it-time-for-new-thinking-about-high-density-lipoprotein-Ht25N4R2BP
Publisher
Wolters Kluwer
Copyright
© 2018 American Heart Association, Inc.
ISSN
1079-5642
eISSN
1524-4636
D.O.I.
10.1161/ATVBAHA.118.310727
Publisher site
See Article on Publisher Site

Abstract

Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester

Journal

Arteriosclerosis, Thrombosis, and Vascular BiologyWolters Kluwer Health

Published: Mar 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off